EMA lists paediatric priorities for off-patent drugs as new EC funding nears
This article was originally published in Scrip
Executive Summary
Following a two-year drought, the European Commission's seventh framework programme (FP7) is to make fresh funding available next year for companies wishing to develop paediatric forms of off-patent drugs.